Moleculin Biotech rises after EMA approves late-stage study of cancer therapy

Moleculin Biotech

12/05/2025 14:05

** Shares of drug developer Moleculin Biotech MBRX.O rise 11.4% to $1.17 premarket

** Co says European Medicines Agency (EMA) has approved its application to conduct late-stage study to test its experimental drug, Annamycin

** Annamycin is potential treatment for acute myeloid leukemia - type of blood and bone marrow cancer

** Co expects to read out interim late-stage study data in H2

** Annamycin also received "fast track" and "orphan drug" designation from U.S. FDA

** As of last close, MBRX down 38.2% YTD

 (Reporting by Siddhi Mahatole)

 ((siddhi.mahatole@thomsonreuters.com))